R&D Pipeline

Pipeline (2021-2030)

Immunology - Others-Synth. (2)

Modality Indication Targets Stage Company Project No. Detail
1 Nonclinical Study for Treatment of IRI Using Bilirubin Nanoparticle (Brixelle)
Others-Synth. Ischemia reperfusion injury ROS Preclinical BILIX HN21C0947
2 Development of functional hyaluronic acid nanoparticle lead compounds for treatment of skin inflammation
Others-Synth. Psoriasis, Contact dermatitis Hyaluronic acid Lead Ajou University HN21C0958